Table 1. Baseline characteristics in the study group.
| Characteristics | Numbers |
|---|---|
| Gender: female | 56 (50%) |
| Age, median and range, years | 31.5 [18–77] |
| BMI†, mean ± SD, kg/m2 | 24.3±4.8 |
| Out-patients | 95 (85%) |
| Inpatients | 17 (15%) |
| CHD of great complexity‡ | 52 (46%) |
| CHD of moderate complexity‡ | 44 (39%) |
| CHD of simple complexity‡ | 16 (14%) |
| Patients with an AEP indication§ | 52 (46%) |
| Patients with implanted pacemaker | 12 (11%) |
| Patients with ICD | 7 (6%) |
| Selected long-term medication | |
| None | 36 (32%) |
| Vitamin K antagonists | 18 (16%) |
| Non-vitamin K antagonist oral anticoagulants (NOAC) | 16 (14%) |
| ACE inhibitors | 14 (13%) |
| Angiotensin receptor blocker | 7 (6%) |
| ASA | 4 (4%) |
| β-blocker | 38 (34%) |
| Diuretics (≥1) | 24 (21%) |
| Pregnant women | 7 (6%) |
| Syndrome-associated CHD | 11 (10%) |
| Trisomy 21 | 3 (3%) |
| Microdeletion syndrome 22q11 | 3 (3%) |
| Holt-Oram syndrome | 1 (1%) |
| Shone syndrome (incomplete) | 1 (1%) |
| Marfan syndrome | 1 (1%) |
| Noonan syndrome | 1 (1%) |
| Williams-Beuren syndrome | 1 (1%) |
†, pregnant women were excluded; ‡, Bethesda criteria of CHD; §, classified high-risk patients in accordance with the AHA guidelines on IE. CHD, congenital heart disease; AHA, American Heart Association; IE, infective endocarditis.